Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

       Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

PR Newswire

PRINCETON, N.J., Jan. 6, 2014

PRINCETON, N.J., Jan.6, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX)
(Soligenix or the Company), a clinical stage biopharmaceutical company focused
on developing products to treat serious inflammatory diseases where there
remains an unmet medical need, as well as developing several biodefense
vaccines and therapeutics, announced today that it has appointed Richard
Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr.
Straube is a board-certified pediatrician with clinical research experience in
host-response modulation. He has had a long and distinguished career of more
than 35 years in both academia and industry, most notably with Centocor,
Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr.
Straube will lead Soligenix's clinical research with primary responsibility
for the execution and completion of its multiple clinical programs, including
its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric
Crohn's disease.

While with Centocor, Dr. Straube was responsible for the initial anti-cytokine
and anti-endotoxin programs targeted at ameliorating inappropriate host
responses to infectious and immunologic challenges. Programs that he has
managed include assessments of immunomodulation using monoclonal removal of
inciting molecular triggers, removal of internal immune-messengers,
augmentation of normal host defenses, and maintenance of normal sub-cellular
function in the face of injury. He was also the founding Chief Medical Officer
for INO Therapeutics and was responsible for the clinical trials and
subsequent approval of inhaled nitric oxide for the treatment of persistent
pulmonary hypertension in the newborn.

Dr. Straube received his medical degree and residency training at the
University of Chicago, completed a joint adult and pediatrician infectious
diseases fellowship at the University of California, San Diego (UCSD), and as
a Milbank Scholar completed training in clinical trial design at the London
School of Hygiene and Tropical Medicine. While on the faculty at the UCSD
Medical Center, his research focused on interventional studies for serious
viral infections.

"We are delighted to welcome Rick to our team, as he will leverage his
extensive drug development expertise in leading our oral mucositis and
pediatric Crohn's disease clinical studies," stated Christopher J. Schaber,
PhD, President and CEO of Soligenix. "His clinical experience with trial
design, conduct and analysis, as well as his background in immunomodulation
and pediatrics will be advantageous to us as we advance our programs." 

About Soligenix, Inc.

Soligenix is a clinical stage biopharmaceutical company developing products to
treat serious inflammatory diseases where there remains an unmet medical need,
as well as developing several biodefense vaccines and therapeutics. Soligenix
is developing proprietary formulations of oral BDP (beclomethasone
17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders
characterized by severe inflammation, including pediatric Crohn's disease
(SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host
disease (orBec^®), as well as developing its novel innate defense regulator
(IDR) technology SGX942 for the treatment of oral mucositis.

Through its BioDefense Division, Soligenix is developing countermeasures
pursuant to the Biomedical Advanced Research and Development Authority (BARDA)
Strategic Plan of 2011-2016 for inclusion in the US government's Strategic
National Stockpile. Soligenix's biodefense products in development are a
recombinant subunit vaccine called RiVax™, which is designed to protect
against the lethal effects of exposure to ricin toxin and VeloThrax™, a
vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated
and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both
RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National
Institute of Allergy and Infectious Diseases (NIAID) grant supporting
development of Soligenix's new vaccine heat stabilization technology known as
ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of
gastrointestinal acute radiation syndrome (GI ARS) under a BARDA contract
award valued up to $26.3 million and a NIAID contract award valued up to $6.4
million. OrbeShield™ has previously demonstrated statistically significant
preclinical survival results in a canine model of GI ARS funded by the NIAID.
Additionally, Soligenix has an exclusive worldwide collaboration with Intrexon
Corporation focused on the joint development of a treatment for Melioidosis, a
high priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company's
website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix,
Inc.'s current expectations about its future results, performance, prospects
and opportunities, including but not limited to, potential market sizes,
patient populations and clinical trial enrollment. Statements that are not
historical facts, such as "anticipates," "estimates," "believes," "intends,"
"potential," or similar expressions, are forward-looking statements. These
statements are subject to a number of risks, uncertainties and other factors
that could cause actual events or results in future periods to differ
materially from what is expressed in, or implied by, these statements.
Soligenix cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on its
technologies, particularly in light of the significant uncertainty inherent in
developing vaccines against bioterror threats conducting preclinical and
clinical trials of vaccines, obtaining regulatory approvals and manufacturing
vaccines, that product development and commercialization efforts will not be
reduced or discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and development
efforts, that it will be able to successfully obtain any further funding to
support product development and commercialization efforts, including grants
and awards, maintain its existing grants which are subject to performance
requirements, enter into any biodefense procurement contracts with the US
Government or other countries, that it will be able to compete with larger and
better financed competitors in the biotechnology industry, that changes in
health care practice, third party reimbursement limitations and Federal and/or
state health care reform initiatives will not negatively affect its business,
or that the US Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. These and other risk
factors are described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, Soligenix's reports on
Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation
to update or revise any forward-looking statements as a result of new
information or future events.

SOURCE Soligenix, Inc.

Website: http://www.soligenix.com
Contact: Joe Warusz, CPA, Acting Chief Financial Officer, (609) 538-8200
 
Press spacebar to pause and continue. Press esc to stop.